Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a BioMedWire editorial examining emerging treatments for multiple sclerosis, a disease affecting more than 2.9 million people globally. The article focuses on the company’s patented drug candidate Lucid-MS, a first-in-class therapy designed to protect the myelin sheath targeted by MS. The program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy to address a significant unmet need in MS treatment.
Multiple sclerosis is a chronic neurodegenerative disease in which the immune system attacks the myelin sheath, the protective covering of nerve fibers, leading to communication problems between the brain and the rest of the body. Current treatments primarily focus on managing symptoms or modulating the immune response, but few directly address myelin repair. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models, positioning it as a potential disease-modifying therapy.
Quantum BioPharma is a biopharmaceutical company building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is advancing Lucid-MS. The company also developed UNBUZZD(TM), an over-the-counter product for alcohol misuse, which was spun out into Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd (as of March 31, 2026) and is entitled to royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains all rights to develop similar products for pharmaceutical and medical uses.
The editorial underscores the importance of Lucid-MS in the context of a large and growing patient population. With over 2.9 million people affected by MS worldwide, there is a pressing need for therapies that can halt or reverse disease progression. If successful in Phase 2 trials, Lucid-MS could offer a new treatment paradigm. The company’s progress is being closely watched by investors and the biotech community, as detailed in the press release available at https://ibn.fm/KdvrI.
Quantum BioPharma’s inclusion in the BioMedWire editorial highlights the potential impact of its research. The article is part of BioMedWire’s coverage of the latest developments in the biotechnology and life sciences sectors. BioMedWire is a specialized communications platform within the Dynamic Brand Portfolio @IBN, which provides access to a vast network of wire solutions, editorial syndication to over 5,000 outlets, and social media distribution. For more information, visit https://www.BioMedWire.com.
The latest news and updates regarding Quantum BioPharma are available in the company’s newsroom at https://ibn.fm/QNTM. As Lucid-MS advances toward Phase 2 trials, the biotech industry and MS community will be watching closely for further developments.
